Advanced search
Publication Cover
Leukemia & Lymphoma Volume 65, 2024 - Issue 1
Submit an article Journal homepage
117
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Sustained long-term remission with tyrosine kinase inhibitor therapy in treatment-refractory B-cell acute lymphoblastic leukemia harboring a RCSD1::ABL2 fusion gene

Mohammad Faizan Zahida Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA;b Malignant Hematology Clinic, Parkland Health and Hospital System, Dallas, TX, USACorrespondence[email protected]
View further author information
&
Radhika Kainthlaa Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA;b Malignant Hematology Clinic, Parkland Health and Hospital System, Dallas, TX, USAView further author information
Pages 123-127 | Received 04 Jul 2023, Accepted 22 Sep 2023, Published online: 09 Oct 2023

References

  • Litzow M. Novel therapeutic approaches for acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2011;25(6):1303–1317. doi:10.1016/j.hoc.2011.09.019
  • Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125–134. doi:10.1016/S1470-2045(08)70339-5
  • Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–1015. doi:10.1056/NEJMoa1403088
  • Greuber EK, Smith-Pearson P, Wang J, et al. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer. 2013;13(8):559–571. doi:10.1038/nrc3563
  • De Braekeleer E, Douet‐Guilbert N, Rowe D, et al. ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol. 2011;86(5):361–371. doi:10.1111/j.1600-0609.2011.01586.x
  • Roberts KG, Li Y, Payne-Turner D, et al. Genomic characterization and experimental modeling of BCR-ABL1-like acute lymphoblastic leukemia. Blood. 2013;122(21):232. doi:10.1182/blood.V122.21.232.232
  • den Boer ML, Cario G, Moorman AV, et al. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Lancet Haematol. 2021;8(1):e55–e66. doi:10.1016/S2352-3026(20)30353-7
  • Lahera A, Vela‐Martín L, López‐Nieva P, et al. Comprehensive characterization of a novel, oncogenic and targetable SEPTIN6:: ABL2 fusion in T‐ALL. Br J Haematol. 2023;202(3):693–698. doi:10.1111/bjh.18901
  • Moorman AV, Schwab C, Winterman E, et al. Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL‐class fusion. Br J Haematol. 2020;191(5):844–851. doi:10.1111/bjh.17093
  • Rohil Y, Shetty D, Narula G, et al. A novel case of ABL2 chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. J Assoc Genet Technol. 2019;45(2):73–76.
  • Raca G, Gurbuxani S, Zhang Z, et al. RCSD1–ABL2 fusion resulting from a complex chromosomal rearrangement in high-risk B-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(4):1145–1147. doi:10.3109/10428194.2014.951851
  • Cario G, Leoni V, Conter V, et al. Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica. 2020;105(7):1887–1894. doi:10.3324/haematol.2019.231720
  • Colicelli J. ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal. 2010;3(139):re6. doi:10.1126/scisignal.3139re6
  • Boer J, Steeghs EM, Marchante JR, et al. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia. Oncotarget. 2017;8(3):4618–4628. doi:10.18632/oncotarget.13492
  • Duhoux FP, Auger N, De Wilde S, et al. The t (1; 9)(p34; q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias. Leuk Res. 2011;35(7):e114–e117. doi:10.1016/j.leukres.2011.02.011
  • Perwein T, Strehl S, König M, et al. Imatinib-induced long-term remission in a relapsed RCSD1–ABL1-positive acute lymphoblastic leukemia. Haematologica. 2016;101(8):e332–e335. doi:10.3324/haematol.2015.139568
  • Scheijen B, Waanders E, van Reijmersdal SV, et al. Focal BTG1 deletions occur in specific precursor B-cell acute lymphoblastic leukemia subtypes at defined hotspots due to aberrant V(D)J recombination. Blood. 2011;118(21):399. doi:10.1182/blood.V118.21.399.399

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.